NewEdge Advisors LLC Has $93.22 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

NewEdge Advisors LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 1.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 120,747 shares of the company’s stock after selling 1,335 shares during the quarter. Eli Lilly and Company comprises approximately 0.6% of NewEdge Advisors LLC’s portfolio, making the stock its 26th largest holding. NewEdge Advisors LLC’s holdings in Eli Lilly and Company were worth $93,217,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Highline Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock valued at $35,000 after buying an additional 20 shares in the last quarter. FPC Investment Advisory Inc. lifted its position in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after acquiring an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $48,000. Compass Financial Services Inc purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $50,000. Finally, Fiduciary Advisors Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $58,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LLY. Guggenheim reduced their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a research report on Monday. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th. Finally, Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,012.00.

Eli Lilly and Company Trading Up 0.3 %

Shares of LLY stock opened at $756.55 on Wednesday. The company has a market capitalization of $717.34 billion, a PE ratio of 64.61, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The business’s fifty day moving average is $832.96 and its 200 day moving average is $821.54. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.